WHO publishes first guidelines for hepatitis B treatment.

WHO publishes first guidelines for hepatitis B treatment. Euro Surveill. 2015;20(10) Authors: Eurosurveillance editorial team PMID: 25788256 [PubMed - in process]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research

Related Links:

ConclusionsDespite being on ART, a significant proportion of HIV/HBV-coinfected individuals present HBV viremia. Characterization of factors that are associated with this finding may help professionals provide better management to these patients.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
We present a case of female patient who was referred to the consultation because she was about to start chemotherapy with an anti-CD20 agent and had a positive anti-HBc and anti-HBs. During routine workup an occult hepatitis B virus infection was diagnosed. Upon further study mutations in the PreCore and Basal Core Promoter regions were identified, as well as, a double genotype D/C. Therapy with tenofovir was initiated before the patient was started on chemotherapy. This case highlights the importance of comprehensive studying of patients who present with apparently resolved chronic hepatitis B virus infection, especially ...
Source: IDCases - Category: Infectious Diseases Source Type: research
Publication date: Available online 9 November 2019Source: Biosensors and BioelectronicsAuthor(s): Masumi Iijima, Tsutomu Nakayama, Shun'ichi KurodaAbstractThe orientation and density of biosensing molecules on sensor chip should be precisely controlled to improve sensitivity and ligand-binding capacity. We previously developed a ∼30-nm bio-nanocapsule (ZZ-BNC), consisting of the hepatitis B virus envelope L protein fused with the tandem form of protein A-derived IgG Fc-binding Z domain (ZZ-L protein). This is used as a robust nanoparticle scaffold to enhance the sensitivity and ligand-binding capacity of IgGs and Fc-fu...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: Entecavir Tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: Entecavir Tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: Entecavir Tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hepatitis | Hepatitis B | Infectious Diseases